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The supply of the right drugs at the right prices has
become an issue of central concern during the last
decade. Many initiatives have contributed to this.
Among them, the developing countries have played a
key role in centring world attention on the
pharmaceutical question and in bringing about
changes in the area. This role, however, has been
insufficiently documented. The present article there-
fore reviews some of the main Third World initiatives
to promote rational and equitable pharmaceutical
policies.
Third World Concern with the Pharmaceutical
Question
The reasons for the deep concern of the developing
countries for the drug question are to be found in their
dependence on external suppliers for pharmaceuticals.2
In 1980 they produced only 11 per cent of the world
output. Except for Argentina, Brazil, Egypt, India and
Mexico, drug production in developing countries is
either wholly non-existent or just limited to
formulation and packaging. Even in countries where
there is some local production, it is mostly accounted
for by wholly-owned subsidiaries of transnational
corporations (TNC5) or by joint ventures in which the
TNCs dominate. TNCs enjoy a considerable market
concentration and domination. Most drugs are sold
under a large number of brand names, which often
exceed 20,000 in number in a single country. Since
doctors and pharmacists mainly determine which
drugs are to be used, it has proved easy to establish
market control through heavy promotion and sales
practices. Most of the research and development
(R & D) is concentrated in the developed countries.
The combined use of the patent and trade mark
systems ensures the dominant producers a large share
of the pharmaceutical market. In consequence, the
costs of imported drugs for developing countries are
excessively high and often account for a third to over a
half of their health budgets. The capacity of the
developing countries to extend health care to their
The views expressed here are personal and are not to be attributed to
UNCTAD.
2 For details see UNCTAD 1982a, particularly paragraphs 35-67.
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populations is thereby severely constrained. Mounting
drug expenditures have limited their policy manoeuvr-
ability to achieve 'Health for Al.l' as called for in the
WHO strategy [WHO 1981].
The vulnerability of the developing countries in the
world pharmaceutical market was eloquently sum-
marised by Mrs. Indira Ghandi, the Prime Minister of
India, in her opening address at the 34th session of the
World Health Assembly, which adopted the 'Global
Strategy for Health for All by the Year 2000':
Affluent societies are spending vast sums of money
understandably on the search for new products and
processes to alleviate suffering and to prolong life.
In the process, drug manufacture has become a
powerful industry, subject to the same driving
considerations as other big industries, that is,
concentration on profit, fierce competition and
recourse to hard-sell advertising. Medicines which
may be of the utmost value to poorer countries can
be bought by us only at exorbitant prices, since we
are unable to have adequate independent bases of
research and production. This apart, sometimes
dangerous new drugs are tried out on populations
of weaker countries although their use is prohibited
within the countries of manufacture. It also
happens that publicity makes us victims of habits
and practices which are economically wasteful or
wholly contrary to good health . . . My idea of a
better ordered world is one in which medical
discoveries would be free of patents and there
would be no profiteering from life or death.
The Key Role of the Non-Aligned Conferences
These concerns have propelled the Third World
countries towards the search for rational and
equitable pharmaceutical policies. This search has
been a part of their initiatives for the establishment of
a New International Economic Order. The pharma-
ceutical question has figured very prominently in these
initiatives, often guided by decisions at the highest
political level.
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In preparation for the 5th conference of heads of state
or government of non-aligned countries held in
Colombo in 1976, a Group of Experts on
Pharmaceuticals was convened in Georgetown,
Guyana, earlier in the same year. The Group had
before it the UNCTAD study, Major Issues in Transfer
of Technology to Developing Countries: a Case Study of
the Pharmaceutical Sector.3
The Colombo conference of the non-aligned countries
adopted a special resolution (number 25) on the
subject.4 The resolution endorsed the following
actions recommended by the Guyana Group of
Experts:
- preparation of a list of priority pharmaceutical
needs of each developing country and formulation
of a basic model list of such needs as a general
guideline for action by developing countries;
- establishment of a national buying agency to
undertake the purchase and supply of pharma-
ceuticals;
- consideration, in the context of the revision of the
industrial property system, of the exclusion of
pharmaceutical products from the grant of patent
This study has usually been ascribed toS. Lall, but for the historical
record, it was published as an UNCTAD document (TD/B/C.6/4)
which exaplained that It had been prepared by Dr Sanjaya Lall in
cooperation with the UNCTAD secretariat.
For the full text of the resolution see [UNCTAD I 982a:Annex 1] or
Patel [1983:291].
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rights, or alternatively, of the curtailment of the
duration of patents for pharmaceuticals;
- elimination, wherever possible, of brand names
and adoption of generic names for pharma-
ceuticals, and provision of information only from
official sources;
- establishment by each developing country of its
own pharmaceutical industry as appropriate,
beginning with formulation and packaging, and
building up to more complex production
activities;
- creation of regional cooperative pharmaceutical
production and technology centres, as proposed by
UNCTAD and UNIDO, to: draw up drug lists;
coordinate R & D; facilitate the transfer of
technology; collect and disseminate information
on pharmaceutical uses and prices, and on
technological capabilities among member
countries; and to coordinate the production and
exchange of drugs between member countries as
well as between regional centres.
The resolution further invited the relevant inter-
national bodies, such as UNCTAD, UNIDO, WHO
Promotion of proprietary products: a continuing problem.
and UNDP, to assist in the achievement of the
objectives outlined above, particularly through the
establishment of appropriate national pharmaceutical
centres in developing countries and of regional
cooperative pharmaceutical production and techno-
logy centres to serve those countries. The Colombo
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non-aligned conference thus delineated the basic lines
of the reform of the pharmaceutical system. It opened
up new dimensions for concerted action at the
national level. It also gave impetus to the involvement
of several international bodies, particularly WHO,
UNCTAD and UNIDO, in pharmaceutical issues.5
For the first time since the Hamurabi Code 4000 years
ago (see p 77), the drug question became an issue of
world concern, involving in it the full political weight
of the non-aligned countries at the level of heads of
state or government.
Swift international action followed the Colombo
conference. A special task force on pharmaceuticals
was established by UNCTAD, WHO, UNIDO, the
United Nations Department of Technical Cooperation
for Development, and the United Nations Action
Programme for Economic Cooperation. The task
force prepared a project entitled, 'Economic and
Technical Cooperation among Developing Countries
in the Pharmaceutical Sector', which was approved by
UNDP for financing,6 and which was executed by the
Government of Guyana in cooperation with the
involved UN agencies. An interregional mission
organised jointly by the various bodies participating in
the project visited several developing countries and
submitted a report in 1979 under the title,
'Pharmaceuticals in the Developing World: Policies
on Drugs, Trade and Production'.7
This report of the interregional mission contained 27
practical recommendations for comprehensive mea-
sures to be taken by developing countries at the
national, regional and interregional levels. They
covered a wide range of interrelated issues concerning
national pharmaceutical policies such as: essential
drugs; quality control; exchange of information;
pooled procurement and cooperative bulk purchases;
price control of imported drugs; unpackaging of
technology imports; excluding pharmaceutical pro-
ducts and processes from patentability or shortening
the duration of patents; abolition of trade marks or
brand names and introduction of the use of generic
names; formulation of new laws and policies;
strengthening national R & D capacity; establishment
of national drug production on a well planned and
phased basis; promotion of medicinal plants; intensive
cooperation among developing countries in exchang-
ing technologies, and establishment of subregional
and regional institutional arrangements (eg pharma-
ceutical centres) to promote such cooperation.
United Nations studies and publications on the subject of
pharmaceuticals have mushroomed in the last several years. Some
of the more important ones are cited in the references under their
respective UN agency publication.
UNDP project INT/009/A/Ol/99.
'For the full text of the conclusions and recommendations of this
report see UNCTAD [1982a:Annex Vor Patel [1983, pp293-296].
This set of recommendations has formed the basis for
new pharmaceutical policies in developing countries.
They are, however, pertinent also to developed
countries, and here is an area where the Third World
has given a lead to the developed world.
The report was also considered at the 6th conference
of the heads of state or government of non-aligned
countries held in Havana in 1979. The conference
endorsed in a special resolution (number 8) the
recommendations of the interregional mission and
called for the establishment of national and regional
centres on pharmaceuticals.8 It directed these centres
to perform some of the following 14 functions:
- elaboration of drug lists and formularies;
- pooled procurement, inventory control and
forecasting systems at the regional level;
- elaboration of legal principles relating to industrial
property;
- elaboration of tenders and master contracts for
drug imports;
- provision of information on sources of supply and
technology;
- assistance in the screening and evaluation of drug
imports;
- price monitoring, control of transfer pricing and
technology import mechanisms;
- promotion of industrial cooperation among
countries;
- assistance in securing equipment imports on the
most economic terms;
- organisation of training of government officials in
health policy, and drug procurement, production,
etc;
- production of pharmaceuticals and intermediates
for several countries;
- research in laboratory, pilot plant, semi-industrial
and industrial processes for the introduction of
new products and the adaptation of imported
technologies;
- preparation of feasibility reports on pharmaceutical
development projects;
- enswing of quality control in respect of raw
materials, intermediates and finished products.
The Colombo and Havana conferences of the non-
aligned countries have thus not only given a composite
package of core elements for new pharmaceutical
policies, but have also clearly determined the
functions of the pharmaceutical centres which must be
established to implement the new policies. The three
years between the conferences saw perhaps the most
active involvement of developing countries in
determining the shape of new drug policies and in
setting an example for the world to follow.
'For the full text of the resolution see UNCTAD [1982a:Annex Vi]
or Paid [1983, pp29l-292].
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Progress Towards New Pharmaceutical
Policies
At the national level
Following the directives of the non-aligned conferences
there was a burst of activity at the national level.
Several countries have already introduced some form
of central procurement system. As a minimum, almost
every country has taken steps towards the coordination
of the purchase of drugs for its public health system,
particularly for the hospitals operating in the public
sector.
A number of developing countries (Argentina, Brazil,
India, Egypt and Mexico) have already created fairly
advanced production capabilities. Several others have
established formulation and packaging units. Others
again have at least begun to assess their national drug
needs, and to formulate policies and plans for a
rational system of procurement and distribution, as
well as for initiating national production of a number
of basic drugs. The establishment of the State
Pharmaceuticals Corporation of Sri Lanka in 1971
initiated an early package of new policies.9 A decade
later, the pharmaceutical movement had so matured
that a fully comprehensive, national drug policy
emerged in Bangladesh in 1982.
However, this swift advance has been marked by a
rising tide of opposition and pressure from the
powerful international pharmaceutical industry to
prevent or water down these new policy departures.
These pressures have been exercised in several
directions: to discredit essential drug lists and the
related policies of buying drugs under generic names
with the weakening or abolition of trade mark
protection; to campaign in favour of industrial
property rights, particularly patents and trade marks,
so discouraging reform of this antiquated and unjust
system; to oppose centralised bulk buying of
pharmaceuticals under open international tender and
the organised public distribution of drugs; and, as a
condition for cooperating in the development of
national industries, to press for the establishment of
subsidiaries or affiliates, agreeing to some weak form
of joint venture only under intense pressure, and even
then maintaining severe restrictive conditions in the
arrangements.
Cooperation at the regional level
The resolutions of both the 5th and the 6th non-
aligned conferences attached great importance to
cooperative initiatives at the regional level. In fact, the
titles of both the resolutions begin with the phrase
'cooperation among developing countries'. Progress
The late Professor Senaka Bibile was the pioneer of this early
initiative, which has continued to influence subsequent thought and
action on the subject; see Bibile [1977].
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The problem.
in this direction has been relatively slow, particularly
because international support for strengthening
economic cooperation among developing countries
has begun to weaken as vested interests have
intensified their opposition. The Caribbean region
and the West African Economic Community appear
to have moved much further along the road to regional
cooperation than other parts of the world.
Caribbean region The UNCTAD and the CAICOM
secretariats organised a joint mission in 1977 to visit
several member countries of the region. ° The report
of this mission was considered at the 4th meeting of the
Conference of Ministers responsible for health in the
Caribbean region, held in St Lucia the following year.
The conference recommended the establishment of a
Caribbean centre for pharmaceuticals and defined a
list of functions to be performed by it.
The broad directives of the ministerial conference
required detailed consideration by experts. Towards
that end, a workshop on trade and technology policies
° See Towards a Regional Pharmaceutical Policy, report of a joint
mission to the Caribbean region organised by UNCTAD.
CARICOM and the trade, transport and industry sector of the
United Nations Action Programme for Economic Cooperation,
Georgetown, Guyana, August-October 1977.
in the pharmaceutical sector in the Carribbean region
was organised in 1980 in Georgetown, Guyana, by the
UNCTAD advisory service on transfer of technology
in cooperation with the CARICOM secretariat. The
participants in the workshop were senior government
officials from the region, drawn from the Ministries of
Health, Planning, and Finance. They made business-
like recommendations on several important subjects,
including policies on selection of drugs for pooled
procurement, procedures for pooled procurement, the
functions of the Caribbean centre for pharmaceuticals,
alternative models for the legal structure of the centre,
and a time-bound programme for the establishment of
the centre)1
Of particular significance was the detailed con-
sideration by the workshop of the alternative models
for the legal structure of the cooperative centre. The
workshop recommended that the model to be used
should be that of an associate institution of the
Caribbean Community, having its own legal status
and operating as a commercial entity with powers to
contract and to create financing systems. Such an
associate institution, as an intergovernmental entity,
would have easier access to funding and other
assistance from international organisations and
governments.
West African Economic Community (CEAO)
UNCTAD, in cooperation with the CEAO secretariat,
organised a mission in 1979 to six member countries of
the Community (Ivory Coast, Mali, Mauritania,
Niger, Senegal and Upper Volta). An expert
committee on pharmaceuticals discussed the report of
this mission and recommended to the Council of
Ministers of CEAO the creation of a technical
committee on drugs to devise practical means of
implementing a subregional technology policy.
Intensive discussion of the next phase of action was
undertaken at a workshop on trade and technology
policies in the pharmaceutical sector organised by the
UNCTAD advisory service in Abidjan, Ivory Coast,
in 1981. The report of the workshop helped evolve the
precise content of the policies to be pursued by the
countries in the West African region, and to define the
scope for cooperative action at the regional and
subregional levels. 12
For the recommendattons of the workshop see UNCTAD [1980a] 2 For the recommendations of the workshop see UNCTAD [1982b:ch
or UNCTAD [1982a:Annex VII]. VI] or UNCTAD [1982a:Annex XIII.
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part of the solution. national drug production.
Other regions There have been several meetings in
other regions devoted to pharmaceutical questions:
for example, ASEAN countries met in Bangkok in
1980, East African countries (Madagascar, Mauritius,
Mozambique and Seychelles) met in Maputo in 1981,
and there have been similar activities in the South
Pacific Economic Community.
All these regional initiatives have raised consciousness
about the issues involved and have prepared the
ground for future action. Unfortunately, there has
been a great imbalance between the strength of the
declared objectives and the vigour with which they
have been pursued. The biggest obstacle has been
posed by the weakening resource support for
translating the broadly accepted schemes into fully
functioning agreements and organisations. These
loose threads need to be gathered up with greater
vigour so that the advances already made are
consolidated in the period ahead.
A new phase in international action
The upsurge of Third World activities during the late
1970s greatly influenced events at the international
level. Two main groups of initiatives at this level merit
special mention here: the identification of a limited list
of essential drugs and movement towards an
international code of pharmaceuticals.
Essential drug lists WHO established an Expert
Committee on the Selection of Essential Drugs, which
has issued two reports [WHO 1977, 1979]. The
committee recommended an essential drug list
consisting of slightly more than 200 items. It thereby
cut through a confused web of some 30,000 brand-
name products: there is now a short list on which
national policy can concentrate.'3 With one bold
stroke it swept away the spurious justifications,
carefully cultivated and promoted at high cost, for the
proliferation of brand names. Subject to the
maintenance of quality standards, the fruitless debate
on the virtues of brand-name versus generic products
can now be deposited in the dustbin of history.
The list of essential drugs was an important step
towards the Declaration of Alma Ata in 1978, paving
the way for the adoption by WHO of its 'Global
Strategy for Health for All by the Year 2000'
[WHO/UNICEF 1978; WHO 1981]. Health is now
recognised as a fundamental right. Its attainment is
accepted as a social responsibility. The supply of the
right drugs at the right prices to all people is a key
element in the strategy. Therefore, the task of devising
new ways to assure such a supply has become all the
more urgent.
Such a list may, of course, be supplemented by some other
medicaments needed for certain specific situations.
76
The world community has created all kinds of schemes
and funds to meet one or another need perceived to
call for special action: children's welfare, population
control, protection of the environment, care of
refugees, to cite only a few that come readily to mind.
Surely health needs are no less urgent than others on
which action has already been taken. If the noble goal
of 'Health for All' is tobe attained by the turn of this
century, there is an urgent need to establish a 'United
Nations Fund for Pharmaceuticals', which can be one
of the mainstays of the implementation of WHO's
global strategy. Proposals for its establishment merit
serious consideration indeed.
Towards an international code on pharmaceuticals In
1981, under mounting pressure of events, the
International Federation of Pharmaceutical Manu-
facturers Associations issued A Code of Pharmaceutical
Marketing Practices» This code marks an acceptance
by the pharmaceutical industry that there is a pressing
need for regulation in this field. It recognises in a
preamble the 'pharmaceutical industry's international
responsibilities' and expresses the industry's prepared-
ness 'to accept certain obligations insofar as their
marketing practices are concerned'. This recognition
is an important beginning. The code itself is a brief
document. After the preamble and a statement on the
obligations of industry, it consists of a suggested code
of marketing practices under the following headings:
General Principles; Medical Representatives; Sym-
posia, Congresses and other Means of Verbal
Communication; Printed Promotional Material; and
Samples. There is also a supplementary statement on
the industry's commitment to observance and
monitoring. The code is limited to marketing, and is to
be voluntary, self-implemented, and self-monitored
by the producers.15
A significant development in this area came with the
involvement of the International Organisation of
Consumers Unions (IOCU) and other non-govern-
mental organisations. There was an International
non-governmental conference on pharmaceuticals in
Geneva in May 1981. Representatives of non-
governmental organisations, coming from 27 countries,
established an international coalition called Health
Action International (HAI). The 10th World
Congress of the IOCU, held at The Hague in June
1981, adopted a resolution requesting IOCU, working
through HAI. to urge WHO and UNCTAD to adopt a
code of practice for the marketing of pharmaceuticals.
Subsequently HAI prepared a discussion document
entitled, 'A Draft International Code of Pharma-
' For the full text of the code see UNCTAD [1982a:Annex VIII] or
Patel [1983, pp313-315].
° For a discussion of the limitations of the code see UNCTAD [1982a:
Annex XI].
ceuticals'. The first draft of the document was
circulated all over the world with a view to obtaining
comments from experts. It underlined the point that
'the scope of the proposed code is such that its
adoption will require the expertise of various United
Nations agencies, most importantly WHO and
UNCTAD'.
The HAI code is based on two premises. First, since
the pharmaceutical industry itself has formulated a
code, the need for a code has already been recognised.
However, its formulation cannot be left to the
producers alone. An instrument to safeguard the
interests of all parties concerned can only be evolved
with the participation of consumers, public authorities
and international organisations. Second, such a code
cannot be limited only to marketing practices. It must
embrace all other important drug issues such as trade,
prices in relation to production costs, management,
distribution, technology, and the entire process of
research and development.
In view of its broad scope, the HAI draft code of 1982
is a very comprehensive document.'6 It consists of 14
articles, most with several sub-articles, covering the
areas of: drug registration; pre-registration clinical
trials of new drugs; objective information on
pharmaceutical products; labelling, package inserts
and promotional material; sales promotion; pricing,
sales and distribution; pharmaceutical technology;
research and development; implementation and
monitoring of the code; and a review procedure to be
adopted by WHO and UNCTAD.
The subject of a pharmaceutical code was discussed at
the 4th session of the UNCTAD Committee on
Transfer of Technology at the end of 1982. Health
Action International had requested the UNCTAD
secretariat to circulate the HAI draft code to the
participants in the committee meeting. The Group of
77 submitted a draft resolution requesting exploration
by WHO and UNCTAD of the possibility of
establishing norms and standards to govern marketing,
distribution, trade and technology in the pharma-
ceutical sector.
The discussions in the UNCTAD Committee were
inconclusive. The Group of 77 insisted on initiating
the exploration of the possibility of establishing
international norms and standards. They were
supported by Group D, the socialist countries of
Eastern Europe. Group B, the developed market
economy countries, however, did not believe that this
question could be settled by international norms,
16 See Health Action International 1982. The text may be purchased
from the publishers of the pharmaceutical news-sheet Scrip, or from
Social Audit Ltd. PO Box Ill, London NW! 8XG. UK. It is also
reproduced in Pate! (ed) [1983, pp3!7-328J.
For details of !he discussion see UNCTAD [1983: paras 135-148].
particularly since WHO was satisfied with the present
progress of discussions in this area. 17 As a result of this
divergence of views the subject was shelved, as is
reflected in the second preambular paragraph to
resolution 21(1V) of the Committee on Transfer of
Technology; this reads, in typical UNese: 'Noting the
separate views of the Groups as expressed at the 4th
session of the Committee on the formulation of
international norms on promotion, distribution, trade
and technology in the pharmaceutical sector'.
The question of a pharmaceutical code was taken up
again at the 5th session of the meeting of the Asian
Ministers of the Group of 77 in Baghdad in 1983. They
adopted a Baghdad Programme of Action. Among
other topics, the programme drew attention to new
issues for the 1980s in the field of technology and
called upon UNCTAD VI to consider 'examining the
possibility of the formulation of international norms
on the marketing, distribution, trade and technology
in pharmaceuticals'. The Ministerial meetings of the
African and Latin American regions of the Group of
77, held respectively in Libreville, Gabon, and in
Cartagena, Colombia, in 1983 also fully supported the
position of the Baghdad Programme of Action. The
Latin American meeting, for example, agreed 'to
decide at an intergovernmental level, on the possibility
of preparing international measures, norms or
standards on promotion, distribution, trade and
technology in the pharmaceutical sector'.
Considerable ground has now been covered on the
promotion and formulation of international norms
and standards - a 'code' - on pharmaceuticals. The
producers have put forward their own limited version.
The consumers and other interested non-governmental
organisations have put forward another, much more
comprehensive, draft document. Intergovernmental
organisations such as WHO and UNCTAD have now
been brought into the debate. The process is under
way - and it will continue.
This debate recalls Hamurabi's Code. Health is such a
vital concern of mankind that provisions concerning
its protection saw their first expression in writing at
the very dawn of civilisation in Babylon some 4,000
years ago. Hamurabi's Code, in articles 215 to 240,
prescribed different physicians' fees according to
classes, and it even regulated damages for unsuccesful
operations. The relevant international organisations
may soon be called upon to play Hamurabi's modern
role.
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